Linda Skibsted Kornerup, Henning Pflugrad, Karin Weissenborn, Hendrik Vilstrup, Gitte Dam
{"title":"Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?","authors":"Linda Skibsted Kornerup, Henning Pflugrad, Karin Weissenborn, Hendrik Vilstrup, Gitte Dam","doi":"10.2147/HMER.S144667","DOIUrl":null,"url":null,"abstract":"<p><p>Liver transplantation (LT) represents the definitive treatment for end-stage liver disease. Cognitive impairment following LT is frequent, referred to as postliver transplant encephalopathy (PLTE). LT removes the underlying chronic liver disease, and until recently hepatic encephalopathy (HE) was assumed to be fully reversible after LT. However, increasing evidence indicates that some degree of cognitive impairment may be present after LT. To which extent PLTE reflects cognitive impairment caused by residual HE (RHE) or the combined effect of other factors affecting brain function before, during, and after LT is not clarified. None of the available psychometric and neurophysiological tests used for detecting HE is shown to be able to distinguish between etiologies. The available, mostly retrospective, clinical studies indicate a high prevalence of abnormal psychometric tests after LT, and not all seem to recover completely. The patients with earlier HE show the most marked improvements, suggesting that the clinical picture of the early PLTE, in fact, represents RHE. Other early post-LT etiologies for PLTE comprise cerebral ischemia, critical illness encephalopathy, and immunosuppressive therapy. Late-onset etiologies comprise diabetes and hypertension, among others. PLTE regardless of etiology is a worrying issue and needs more attention in the form of mechanistic research, development of diagnostic/discriminative tools, and standardized prospective clinical studies.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"11 ","pages":"41-46"},"PeriodicalIF":2.6000,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/40/hmer-11-41.PMC6456244.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Medicine : Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HMER.S144667","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Liver transplantation (LT) represents the definitive treatment for end-stage liver disease. Cognitive impairment following LT is frequent, referred to as postliver transplant encephalopathy (PLTE). LT removes the underlying chronic liver disease, and until recently hepatic encephalopathy (HE) was assumed to be fully reversible after LT. However, increasing evidence indicates that some degree of cognitive impairment may be present after LT. To which extent PLTE reflects cognitive impairment caused by residual HE (RHE) or the combined effect of other factors affecting brain function before, during, and after LT is not clarified. None of the available psychometric and neurophysiological tests used for detecting HE is shown to be able to distinguish between etiologies. The available, mostly retrospective, clinical studies indicate a high prevalence of abnormal psychometric tests after LT, and not all seem to recover completely. The patients with earlier HE show the most marked improvements, suggesting that the clinical picture of the early PLTE, in fact, represents RHE. Other early post-LT etiologies for PLTE comprise cerebral ischemia, critical illness encephalopathy, and immunosuppressive therapy. Late-onset etiologies comprise diabetes and hypertension, among others. PLTE regardless of etiology is a worrying issue and needs more attention in the form of mechanistic research, development of diagnostic/discriminative tools, and standardized prospective clinical studies.
肝移植(LT)是治疗终末期肝病的最终方法。肝移植后经常出现认知障碍,称为肝移植后脑病(PLTE)。肝移植可消除潜在的慢性肝病,直到最近,肝性脑病(HE)一直被认为在肝移植后是完全可逆的。然而,越来越多的证据表明,LT术后可能会出现一定程度的认知障碍。PLTE在多大程度上反映了残余肝性脑病(RHE)引起的认知功能障碍,或在LT之前、期间和之后影响大脑功能的其他因素的综合影响,目前尚未明确。用于检测 HE 的现有心理测量和神经生理学测试均无法区分不同的病因。现有的临床研究大多是回顾性的,这些研究表明,LT 后心理测试异常的发生率很高,而且似乎并非所有患者都能完全康复。早期 HE 患者的病情改善最为明显,这表明早期 PLTE 的临床表现实际上代表了 RHE。LT后PLTE的其他早期病因包括脑缺血、重症脑病和免疫抑制治疗。晚期病因包括糖尿病和高血压等。无论病因如何,PLTE 都是一个令人担忧的问题,需要通过机理研究、开发诊断/鉴别工具和标准化前瞻性临床研究等形式给予更多关注。
期刊介绍:
Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.